放射性复发前列腺癌挽救性冷冻手术的功能与肿瘤学结局
本研究回顾性分析了169例经活检证实的放射性复发前列腺癌患者,均接受挽救性冷冻手术(SCS)。中位随访36个月,5年无生化复发生存率为52%(95%CI 43-62%),8年为45%(95%CI 35-57%);5年无ADT生存率为70%(95%CI 62-79%)。Clavien-Dindo≥III级并发症发生率为1.2%,但新发尿失禁发生率为19%,新发勃起功能障碍为92%,持续性尿瘘为6.5%。
要点
- SCS肿瘤学结局可接受,5年BRFS 52%(95%CI 43-62%)。
- 严重并发症(≥III级)发生率低(1.2%),但尿失禁(19%)和尿瘘(6.5%)不容忽视。
- 新发勃起功能障碍发生率高达92%。
核心结论
- 对于放射性复发前列腺癌,SCS显示出可接受的肿瘤学结局。
- 严重并发症如尿失禁和尿瘘的发生率不应低估。
研究设计与样本
- 回顾性分析169例连续活检证实的放射性复发前列腺癌患者。
- 所有患者于2006-2018年在单一转诊中心接受SCS。
主要发现
- 中位随访36个月(IQR 18-66)。
- 5年和8年无生化复发生存率(Phoenix定义)分别为52%(95%CI 43-62%)和45%(95%CI 35-57%)。
- 5年无ADT生存率为70%(95%CI 62-79%)。
- Clavien-Dindo≥III级并发症发生率为1.2%(2/169)。
- 新发尿失禁(>1垫/24h)发生率为19%(29/156),新发勃起功能障碍为92%(57/62),持续性尿瘘为6.5%(11/169)。
关键数值与推荐
- 生化复发根据Phoenix定义(PSA nadir +2 ng/mL)判定。
- 多因素分析显示初始诊断时PSA水平、初始治疗、原发治疗与SCS间隔、SCS时年龄和SCS后PSA nadir是BRFS的显著影响因素。
临床怎么用
- SCS可作为放射性复发前列腺癌的挽救治疗选择,但需充分告知患者尿失禁、勃起功能障碍和尿瘘风险。
局限性
- 回顾性单中心研究设计。
- 功能结局基于患者报告,可能存在信息偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the oncological and functional outcomes of salvage cryosurgery (SCS) for radiorecurrent prostate cancer (rrPCa). PATIENTS AND METHODS: A total of 169 consecutive patients with biopsy confirmed rrPCa were retrospectively analysed. All patients underwent SCS in a single referral centre between 2006 and 2018. The primary outcome was biochemical recurrence-free survival (BRFS) according to the Phoenix definition (prostate-specific antigen [PSA] nadir +2 ng/mL). The secondary outcomes were overall survival, BRFS defined as a PSA level of >0.5 ng/mL, metastasis-free survival, androgen-deprivation therapy (ADT)-free survival, and functional outcomes. Complications were classified according to the Clavien-Dindo system. PSA was measured every 3-6 months postoperatively. Functional outcomes were scored as reported by patients at outpatient visits. Kaplan-Meier survival analysis and uni- and multivariable Cox regression were performed. RESULTS: The median (interquartile range) follow-up was 36 (18-66) months. The BRFS after 5 and 8 years was 52% (95% confidence interval [CI] 43-62%) and 45% (95% CI 35-57%), respectively. At multivariable analysis PSA level at initial diagnosis, initial treatment, interval between primary treatment and SCS, age at SCS, and post-SCS PSA nadir were significant factors for BRFS. The 5-year ADT-free survival was 70% (95% CI 62-79%). Clavien-Dindo Grade ≥III complications occurred in 1.2% (two/169) of patients. In all, 19% (29/156) of patients had new-onset urinary incontinence defined as >1 pad/24 h and 92% (57/62) of patients had new-onset erectile dysfunction. Persistent urinary fistula occurred in 6.5% (11/169) of patients. CONCLUSIONS: The present study shows acceptable oncological outcomes of SCS considering the salvage character of the treatment. The occurrence of serious complications such as urinary incontinence and fistula should not be underestimated.
引用
- Exterkate L, Peters M, Somford DM, et al. Functional and oncological outcomes of salvage cryosurgery for radiorecurrent prostate cancer. BJU Int. 2020. PMID: 33043572. doi:10.1111/bju.15269
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。